4-[(2-{[4-({8-[2-(acetyloxy)-1-hydroxypropan-2-yl]-2-oxo-2H,8H,9H-furo[2,3-h]chromen-9-yl}oxy)-3-methyl-4-oxobutan-2-yl]sulfanyl}-1-[(carboxymethyl)-C-hydroxycarbonimidoyl]ethyl)-C-hydroxycarbonimidoyl]-2-aminobutanoic acid

Metabolite details

Identifier

USGIWPWJPGCXRJ-UHFFFAOYSA-N

InChI Key

USGIWPWJPGCXRJ-UHFFFAOYSA-N

IUPAC name

5-[[3-[4-[[8-(2-acetyloxy-1-hydroxypropan-2-yl)-2-oxo-8,9-dihydrouro[2,3-h]chromen-9-yl]oxy]-3-methyl-4-oxobutan-2-yl]sulanyl-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-2-amino-5-oxopentanoic acid

Preferred name

4-[(2-{[4-({8-[2-(acetyloxy)-1-hydroxypropan-2-yl]-2-oxo-2H,8H,9H-furo[2,3-h]chromen-9-yl}oxy)-3-methyl-4-oxobutan-2-yl]sulfanyl}-1-[(carboxymethyl)-C-hydroxycarbonimidoyl]ethyl)-C-hydroxycarbonimidoyl]-2-aminobutanoic acid

INN name

—

Synonym

—

ChEBI

CHEBI:184862

Reactome pathways

• No Reactome pathways listed for this metabolite.

Observed in studies

• Bioaccumulation of therapeutic drugs by human gut bacteria: cross-feeding metabolite analysis (FIA-MS) (E.rectale;S.salivarius assays)

Observed in differential profiles

• G4_Eubacterium_rectale_DMSO_30_vs_G3_Eubacterium_rectale_Duloxetine_47